Reversing cachexia

Michael J. Tisdale*

*Corresponding author for this work

Research output: Contribution to journalArticle


Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

Original languageEnglish
Pages (from-to)511-512
Number of pages2
Issue number4
Publication statusPublished - 20 Aug 2010

Fingerprint Dive into the research topics of 'Reversing cachexia'. Together they form a unique fingerprint.

  • Cite this

    Tisdale, M. J. (2010). Reversing cachexia. Cell, 142(4), 511-512.